COLCHESTER, VERMONT and YOKOHAMA, Japan, 11 July 2023 – Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company,...
Yokohama Japan, 25 May 2023: We are pleased to announce the results of the Phase II clinical trial in Japan (protocol number: RS-01) of our regenerative medicine product Stemchymal® (allogeneic...
Yokohama Japan, 23 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with...
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
Yokohama Japan, 23 November 2022: REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings. Histocell is a CDMO based in...
REPROCELL is On the Road at ISSCR 2022
This June, REPROCELL’s experts will be busy. We will be joining with stem cell scientists at ISSCR 2022 to allow scientists an opportunity to meet in person with REPROCELL’s experts at Booth 310 and...
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
Yokohama Japan, 02 September 2021: REPROCELL have signed a Strategic Collaboration Agreement with TEXCELL JAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The...
Yokohama Japan, 18 August 2021: REPROCELL have signed a Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group...
New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs
[Glasgow, UK] REPROCELL has contributed to a novel publication detailing advancements in induced pluripotent stem cell (iPSC) reprogramming. The paper, published in New Biotechnology by Dr Amer Rana...
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
[Hyderabad, India] Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced Bioserve Biotechnologies Pvt Ltd (REPROCELL’s 100% owned subsidiary) as the...
REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells
Yokahoma, Japan: REPROCELL announce the launch of StemRNA™ Entero: human iPSC-derived intestinal epithelial cells. StemRNA™ Entero cells are intestinal epithelial cells derived from human iPSCs. This...
REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development
Maryland, September 2019: The Maryland based REPROCELL Inc. subsidiary, REPROCELL USA Inc. announces that they have received a $292,580 grant from the Maryland Stem Cell Research Fund (MSCRF)....
PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe
Yokohama, Japan, & San Carlos, California, USA — REPROCELL, Inc., and NeuCyte, Inc., today announced a new distributorship. Although NeuCyte has direct sales in North America, this new...
The lab-scale system will allow researchers to study and culture stem cells in suspension Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor...
Yokohama Japan – REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in...
New Cell Therapies for Central Nervous System Diseases Using IPSC-Derived Products YOKOHAMA, JAPAN & SALT LAKE CITY, UTAH – November 29th, 2017 – REPROCELL, Inc. announced a collaborative research...
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
REPROCELL announces an entrustment contract with Healios K.K. (headquarters: Minato Ward, Tokyo; president and CEO: Tadanao Kagimoto; hereafter, Healios) for sample testing support of human clinical...
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
Today, REPROCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL)...
Company: REPROCELL, Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info-us@reprocell.com “ReproHP Medium,” a highly functional culture fluid for human primary liver...
Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells
Company: REPROCELL,Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info-us@reprocell.com We would like to inform you that a patent application concerning an...
Company: REPROCELL,Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info_en@reprocell.com Group affiliate Stemgent Inc. (US) is pleased to announce the publication of...